The Asia-Pacific Continuous Glucose Monitoring System (CGMS) market is predicted to evolve at 34.81% CAGR over the forecast period of 2019-2027, collecting a total of $XX million.
While the Asia-Pacific Self-Monitoring of Blood Glucose (SMBG) market is predicted to evolve at 6.28% CAGR over the forecasted period, collecting a total of $XX million by the end of 2027.
Over the last three decades, there has been an exponential increase in the number of diabetic patients, particularly in developing economies where more than XX% of the people are living with diabetes. The prevalence rate of diabetes is said to be increasing in developing countries owing to rapid and ongoing socioeconomic transition, and as a result, the healthcare expenditure had risen. This increase in expenditure is anticipated to create opportunities for the CGMS market in the upcoming years. China’s glucose monitoring system market accounted for the highest revenue share in 2018, and the country currently has the highest diabetes prevalence rate because of the growing population.
Asia-Pacific region enjoys a presence of eminent market players like Becton Dickinson And Company, Roche Diagnostics, Morepen Laboratories Ltd., Insulet Corp., Wockhardt, Ypsomed, ARKRAY Inc., Senseonics Inc., Tandem Diabetes Care, Ascensia, GlySens Inc., B Braun Melsungen AG, Terumo, Apex Biotechnology Corp., Medtronic, Nemaura Medical Inc., I-Sens Inc., Johnson and Johnson, Abbott, Dexcom, and others.